deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03848481

CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

Cannabidivarin (CBDV) vs. Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)

Sponsor: Foundation for Prader-Willi Research

Conditions Prader-Willi Syndrome
Interventions CBDV Compound Placebo
Updated 19 times since 2019 Last updated: Nov 18, 2024 Started: Nov 23, 2020 Primary completion: Oct 31, 2024 Completion: Oct 31, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Prader-Willi Syndrome and is currently completed. Foundation for Prader-Willi Research leads this study, which shows 19 recorded versions since 2020 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Feb 2020 · 9 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Dec 2020 · 4 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jan 2022 · 12 months · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~Sep 2022 · 6 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Nov 2023 · 10 months · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Sep 2025 · 9 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Dec 2024 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 14 earlier versions

  1. Nov 2023 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Jan 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  3. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE2

  4. Mar 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Jan 2022 [monthly]

    Recruiting PHASE2

  7. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Aug 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  9. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Apr 2020 — Jun 2020 [monthly]

    Not Yet Recruiting PHASE2

  11. Mar 2020 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE2

  12. Feb 2020 — Mar 2020 [monthly]

    Not Yet Recruiting PHASE2

  13. May 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE2

  14. Mar 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Foundation for Prader-Willi Research
  • GW Pharmaceuticals Ltd
  • Montefiore Medical Center
Data source: Montefiore Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations